There is a strong rationale to use plasma galectin-3 as a prognostic biomarker in COVID-19 and theorizes that inhibiting galectin-3 is a feasible therapeutic approach. Galectin-3 drives inflammation in immune responses, fibrosis, and hypoxia which are part of the COVID-19 pathology. Since there are tolerable Galectin-3 inhibitors clinical trials are feasible. Galectin-3 is also a prognostic biomarker for severe COVID-19.